Form 8-K Emergent BioSolutions For: Aug 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Emergent BioSolutions (EBS) Tops Q2 EPS by 18c
August 6, 2015 9:19 AM EDTEmergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.36, $0.18 better than the analyst estimate of $0.18. Revenue for the quarter came in at $126.1 million versus the consensus estimate of $114.25 million.
Emergent BioSolutions reaffirmed FY2015 guidance.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
... MoreEmergent BioSolutions (EBS) to Spin Biosciences Business Unit into Separate, Publicly-Traded Company
August 6, 2015 7:28 AM EDTEmergent BioSolutions (NYSE: EBS) announced that its Board of Directors has authorized management to pursue a tax-free spin-off of the company's Biosciences business into a separate, stand-alone publicly-traded company. The spin-off is expected to create two independent public companies with distinct strategic plans, growth strategies, and operational and development priorities.
The new Biosciences company, to be named at a later date, will focus on providing novel oncology and hematology therapeutics to meaningfully improve patients' lives. The core technology of the Biosciences company will be its ADAPTIR platform applied to immuno-oncology. Emergent BioSolutions... More
